Rivernorth Capital Management’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Rivernorth Capital Management’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-102,372	Closed	-$1.06M	–	512
2025 Q3	$1.06M	Sell	102,372 -318,126	-76%	-$3.33M	0.06%	230
2025 Q2	$4.34M	Hold	420,498	–	–	0.24%	121
2025 Q1	$4.28M	Buy	+420,498	New	+$4.24M	0.23%	112

Other funds holding DMAAU

Kryger Capital London, United Kingdom $1.75B AUM 102.57% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

RCM

Robinson Capital Management Grosse Pointe Farms, Michigan $226M AUM 6.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rivernorth Capital Management's DMAAU Position: Q4 2025 in Review

Rivernorth Capital Management sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q4 2025, closing a stake of 102,372 shares — an estimated $1.06M sold.

Rivernorth Capital Management first reported a position in DMAAU in Q1 2025 and held it in 3 quarters. The position peaked at $4.34M in Q2 2025. 5 funds tracked by Wall St. Rank hold DMAAU as of Q4 2025.

Rivernorth Capital Management reported no remaining Drugs Made In America Acquisition Corp Units position as of Q4 2025 after selling out during the quarter.
Rivernorth Capital Management sold 102,372 Drugs Made In America Acquisition Corp Units shares in Q4 2025, an estimated $1.06M.
Rivernorth Capital Management first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 3 quarters.
Rivernorth Capital Management's Drugs Made In America Acquisition Corp Units position peaked at $4.34M in Q2 2025.
5 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q4 2025.

Based on Rivernorth Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.